PALO ALTO VETERANS INSTITUTE FOR RESEARCH

As filed

Subsection

03

NTEE code

H00E

Classification

8000

Street

3801 MIRANDA AVE

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2024

• CLINICAL TRANSLATION OF ALLOGENEIC REGENERATIVE CELL THERAPY FOR WHITE MATTER STROKE AND VASCULAR DEMENTIA. PRINCIPAL INVESTIGATOR: IRENE LORENZO LLORENTE, PH.D.STROKE IS THE LEADING CAUSE OF ADULT DISABILITY AND THE SECOND LEADING CAUSE OF DEMENTIA. WHITE MATTER STROKE (WMS) CONSTITUTES UP TO 30% OF ALL STROKE SUBTYPES AND IS A DISTINCT PROCESS FROM "LARGE ARTERY STROKE." WMS BEGINS AS SMALL INFARCTS IN DEEP PENETRATING BLOOD VESSELS IN THE BRAIN BUT PROGRESSES, ACCUMULATES, AND EXPANDS FROM PREEXISTING LESIONS INTO ADJACENT WHITE MATTER TO PRODUCE HEMIPARESIS WITH INCOMPLETE RECOVERY, GAIT ABNORMALITIES, COGNITIVE DECLINE, AND EXECUTIVE DYSFUNCTION CHARACTERISTIC OF VASCULAR DEMENTIA (VAD). UNLIKE LARGE ARTERY STROKE, WMS DOES NOT DAMAGE NEURONAL CELL BODIES BUT PRIMARILY AFFECTS AXONAL TRACTS AND GLIAL CELLS. A CELL-BASED THERAPY CAPABLE OF REPLACING LOST GLIA AND INDUCING STRUCTURAL REPAIR IN WMS/VAD HOLDS GREAT PROMISE. WE HAVE DEVELOPED A UNIQUE ALLOGENEIC HUMAN INDUCED PLURIPOTENT STEM CELL (HIPSC)-DERIVED GLIAL ENRICHED PROGENITOR (GEP) CELL THERAPY PRODUCT FOR THE TREATMENT OF WMS AND VAD. PRECLINICAL STUDIES DEMONSTRATE THAT HIPSC-GEPS TRANSPLANTED INTO THE BRAIN AFTER WMS/VAD PROMOTE MOTOR AND COGNITIVE RECOVERY THROUGH MULTIPLE MECHANISMS OF ACTION, INCLUDING AXONAL GROWTH, ASTROCYTIC MODULATION, OLIGODENDROCYTE DIFFERENTIATION, AND REMYELINATION. THIS YEAR, WE ACHIEVED A SUCCESSFUL PRE-IND MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR GEP-101 (HIPSC-GEPS) ON FEBRUARY 26, 2026. THE DISCUSSION, INFORMED BY THE FDA'S PRELIMINARY WRITTEN RESPONSES DATED FEBRUARY 23, 2026, FOCUSED ON FOUR PRIMARY AREAS: (1) SUITABILITY OF THE HIPSC CELL LINE AND DONOR ELIGIBILITY TESTING, (2) ADEQUACY OF THE PROPOSED CLINICAL DELIVERY DEVICE AND ADDITIONAL NONCLINICAL EVALUATION NEEDS, (3) REQUIREMENTS FOR DEVICE COMPATIBILITY TESTING TO ENSURE PRODUCT QUALITY AND DOSE ACCURACY, AND (4) QUALIFICATION OF CERTAIN MANUFACTURING RAW MATERIALS, INCLUDING THE VEEV RNA REPLICON USED DURING CELL REPROGRAMMING. OVERALL, THE FDA AGREED WITH ALL POSITIONS PRESENTED, CLARIFYING EXPECTATIONS FOR MANUFACTURING CONTROLS, DEVICE USE, AND SUPPORTING NONCLINICAL DATA PRIOR TO IND SUBMISSION.FOLLOWING THE PRE-IND MEETING, WE HAVE SUBMITTED A NEW GRANT PROPOSAL TO SECURE THE NEXT ROUND OF FUNDING AND CONTINUE ADVANCING TOWARD IND APPROVAL AND FUTURE CLINICAL TRANSLATION.

  Expenses $1,310,697

• Withheld by Nonprofiteer: this text may name a private individual.

  Expenses $1,238,218

• ALL OF US RESEARCH PROGRAM. PRINCIPAL INVESTIGATORS: PHILIP TSAO, PH.D. THE ALL OF US RESEARCH PROGRAM (ALL OF US) IS A LARGE COLLABORATIVE INITIATIVE SPONSORED BY THE NATIONAL INSTITUTES OF HEALTH (NIH). ALL OF US INCLUDES A CONSORTIUM OF AWARDEES FROM MULTIPLE INSTITUTIONS, INCLUDING THE DEPARTMENT OF VETERANS AFFAIRS. ALL OF US IS WORKING TO IMPROVE HEALTHCARE THROUGH RESEARCH BY BUILDING A DIVERSE DATABASE OF PARTICIPANT SELF-REPORT INFORMATION, BIOSPECIMENS, AND ELECTRONIC HEALTH RECORDS THAT CAN INFORM FUTURE RESEARCH ON A VARIETY OF HEALTH CONDITIONS. VA PARTICIPATION IN ALL OF US IS OVERSEEN BY TWO CO-PIS, LOCATED AT THE VA PALO ALTO HEALTHCARE SYSTEM AND THE VA BOSTON HEALTHCARE SYSTEM. THESE TWO INSTITUTIONS SERVE AS THE COORDINATING CENTERS FOR VA RESPONSIBLE FOR CENTRALIZED RECRUITMENT, ENGAGEMENT CAMPAIGNS, AND COMPLIANCE WITH PROGRAM REQUIREMENTS.

  Expenses $1,062,166

• PAVIR IS PRIVILEGED TO WORK WITH A LARGE COMMUNITY OF UNIQUELY TALENTED MEDICAL RESEARCHERS ACROSS A BROAD SPECTRUM OF RESEARCH AREAS AS WE FULFILL OUR MISSION OF ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. THE RANGE OF RESEARCH ACTIVITIES IS BROAD AND INCLUDES SPECIAL EMPHASIS ON MAJOR DISEASE CATEGORIES, ALL OF WHICH ARE PREVALENT IN THE VA'S PATIENT POPULATION. THESE INCLUDE CARDIOVASCULAR MEDICINE, MENTAL HEALTH, CHRONIC INFLAMMATORY DISEASE, STEM CELL/REGENERATIVE MEDICINE, PAIN, SLEEP DISORDERS, AND MANY OTHERS. IN ADDITION TO DISEASE SPECIFIC RESEARCH, PAVIR IS ENGAGED IN SUPPORTING RESEARCH AIMED AT ENHANCING HEALTH CARE. PAVIR'S RESEARCH PORTFOLIO INCLUDES COMPARATIVE STUDIES IN WHICH RESEARCH TEAMS ARE LEARNING WHICH TREATMENTS ARE SUPERIOR TO OTHERS, HOW TO AUGMENT OR IMPROVE STANDARD OF CARE, AS WELL AS HOW TO ENHANCE THE OPERATION OF HEALTH CARE. FURTHERMORE, PAVIR IS SUPPORTING EDUCATIONAL ACTIVITIES, ESPECIALLY IN AREAS OF ADVANCING CLINICAL CARE FOR VETERANS AND FOSTERING THE PROFESSIONAL DEVELOPMENT OF OUR EXPERT STAFF.

  Expenses $24,180,777 · Revenue $10,144,436

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here. A text marked withheld matched a screen for wording that may name a private individual, such as an honorific or "in memory of". Most of what it withholds names no one; it is withheld so that what does is never shown.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

The first 25 listed. Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2024

  Revenue

  $35,854,131

  Expenses

  $33,029,388

  Contributions

  $25,318,301

  Grants paid

  $0

• 2023

  Revenue

  $31,646,627

  Expenses

  $34,355,201

  Contributions

  $23,286,921

  Grants paid

  $0

• 2022

  Revenue

  $30,503,398

  Expenses

  $30,736,665

  Contributions

  $21,413,596

  Grants paid

  $0

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $29,922,772

  Expenses

  $29,764,131

  Assets (EOY)

  $15,643,008

• 2020 · 990

  Revenue

  $29,400,012

  Expenses

  $28,118,941

  Assets (EOY)

  $15,189,973

• 2019 · 990

  Revenue

  $29,572,642

  Expenses

  $31,188,918

  Assets (EOY)

  $12,982,406

• 2018 · 990

  Revenue

  $31,059,629

  Expenses

  $30,708,326

  Assets (EOY)

  $12,525,941

• 2017 · 990

  Revenue

  $28,157,044

  Expenses

  $28,466,853

  Assets (EOY)

  $12,338,139

• 2016 · 990

  Revenue

  $28,240,385

  Expenses

  $27,685,878

  Assets (EOY)

  $13,757,503

• 2015 · 990

  Revenue

  $28,219,973

  Expenses

  $26,886,139

  Assets (EOY)

  $10,945,542

• 2014 · 990

  Revenue

  $27,288,665

  Expenses

  $26,508,261

  Assets (EOY)

  $9,968,460

• 2013 · 990

  Revenue

  $24,249,138

  Expenses

  $24,309,655

  Assets (EOY)

  $8,621,232

• 2011 · 990

  Revenue

  — not reported

  Expenses

  $24,563,589

  Assets (EOY)

  $8,704,349

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

No itemized grants to organizations. Schedule I is filed only by organizations that granted more than $5,000 to a recipient, so most filers have none.

Grants received

• AMERICAN HEART ASSOCIATION INC

  $3,217,828

  2022 · RESEARCH

• AMERICAN HEART ASSOCIATION INC

  $1,144,580

  2023 · RESEARCH

• FOUNDATION FOR ATLANTA VETERANS EDUCATION AND RESEARCH INC

  $256,769

  2022 · COLLABORATION TO QUANTIFY THE BURDEN OF NOROVIRUS GASTRO

• FOUNDATION FOR ATLANTA VETERANS EDUCATION AND RESEARCH INC

  $202,119

  2023 · COLLABORATION TO QUANTIFY THE BURDEN OF NOROVIRUS GASTRO

• VANDERBILT UNIVERSITY MEDICAL CENTER

  $176,094

  2024 · Research

• VANDERBILT UNIVERSITY MEDICAL CENTER

  $175,701

  2023 · Research

• JOHNS HOPKINS UNIVERSITY

  $110,745

  2024 · SUB-AWARD

• THE MEDICAL COLLEGE OF WISCONSIN INC

  $107,796

  2022 · RESEARCH SUBAWARD

• YALE UNIVERSITY

  $100,010

  2023 · SUBAWARD - SPONSORED RESEARCH

• TRUSTEES OF BOSTON UNIVERSITY

  $81,889

  2024 · RESEARCH

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations

From Schedule R Part II, where a filer lists the tax-exempt organizations it is related to by control. It does not record shared board members or money.

Other IRS files